JIUYUAN GENE (02566) saw its stock soar 5.63% in intraday trading on Wednesday, following the release of its interim results for the first half of 2025. The biotech company's shares climbed despite reporting a decline in overall revenue and profit, as investors focused on promising growth in its orthopedic product segment.

According to the earnings report, JIUYUAN GENE's revenue for the six months ended June 30, 2025, reached RMB 639 million, representing a 9.05% year-on-year decline. Net profit attributable to shareholders fell 14.4% to RMB 90.174 million. However, the company's orthopedic product sales volume increased by over 10% compared to the same period last year, with hospital penetration rates continuing to improve.

Despite the overall revenue dip, investors appeared optimistic about JIUYUAN GENE's future prospects. The company's management highlighted its focus on implementing differentiated commercial policies aimed at stabilizing existing markets and cultivating new ones. These strategies are part of JIUYUAN GENE's efforts to achieve steady growth in full-year business revenue, potentially explaining the positive market reaction to the mixed earnings report.